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BACKGROUND: Low serum sodium has recently been associated with poor survival in localised renal cell carcinoma (RCC). We now
show the prognostic effect of serum sodium in patients with metastatic RCC (mRCC).
METHODS: Cohort A comprised 120 consecutive patients with mRCC receiving subcutaneous, low-dose interleukin-2 and
interferon-a. Hyponatremia was assessed in univariate and multivariate analyses. An independent cohort of another 120 patients with
mRCC was used for validation (cohort B).
RESULTS: In cohort A, estimated 5-year survival was 15% and median survival was 15.1 months. Serum sodium ranged between 126
and 144mM. Twenty-four patients (20%) had serum sodium levels below normal range (o136mM). In multivariate analysis, significant
independent risk factors for short survival were low serum sodium (P¼0.014), high neutrophils (P¼0.018), lactate dehydrogenase
41.5 upper normal level (P¼0.002), and number of metastatic sites (þ3) (P¼0.003). In cohort B, serum sodium ranged between
128 and 146mM. Seventeen patients (14%) had sodium levels below normal range. In multivariate analysis, serum sodium was
validated as an independent prognostic factor (P¼0.001). A significant association between lack of response and hyponatremia was
observed in both cohorts (P¼0.003 and P¼0.02, respectively).
CONCLUSION: Low serum sodium is a new, validated, independent prognostic, and predictive factor in patients with mRCC.
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Renal cell carcinoma (RCC) represents approximately 2% of
all cancers worldwide (Parkin et al, 2005). Approximately, half
of the patients will suffer from metastatic disease, and untreated,
the 5-year survival rate for these patients is o2% (Cohen and
McGovern, 2005). Selection of patients to optimal treatment
are based on prognostic models incorporating patient and disease
related clinical prognostic factors (Choueiri, 2009, pp 154–166)
with the Memorial Sloan Kettering Cancer Center (MSKCC)
prognostic model as the most extensively used (Motzer et al,
2002). However, further examination of potentially new predictive
and prognostic markers is highly warranted.
Serum sodium is a readily available, easily obtained and
routinely measured plasma electrolyte. However, low serum
sodium, hyponatremia, is an often underdiagnosed and untreated
electrolyte disturbance. Until recently, no predictive or prognostic
role of low serum sodium has been recognised. This is despite
hyponatremia is the most common electrolyte disorder in
hospitalised patients (Asadollahi et al, 2007; Patel and Balk,
2007; Ghali, 2008). However, hyponatremia is associated with poor
outcome in several medical conditions, such as liver cirrhosis
(Luca et al, 2007; Kim et al, 2008), congestive heart failure
(Gheorghiade et al, 2007; Rossi et al, 2007; Gotsman et al, 2008;
Rusinaru et al, 2009), and infectious diseases as pneumonia
(Nair et al, 2007), childhood meningitis (Chao et al, 2008), and
necrotising soft-tissue infection (Yaghoubian et al, 2007). More-
over, hyponatremia has recently been associated with poor overall
survival in hepatocellular carcinoma (Huo et al, 2008), gastric
cancer (Kim et al, 2007), and small cell lung cancer (Gandhi and
Johnson, 2006). In localised RCC, serum sodium level below
median values has recently been associated with poor disease free
and overall survival after nephrectomy (Vasudev et al, 2008).
Hyponatremia may thus be an indicator of adverse prognosis in
non-malignant as well as malignant diseases.
The objective of this study was to evaluate the predictive and
prognostic role of hyponatremia in patients with metastatic RCC
(mRCC) in two consecutive groups of patients.
MATERIALS AND METHODS
Patients
A cohort of 123 consecutive patients was treated with low-dose,
subcutaneous interleukin-2 (IL-2) and interferon (IFN)-a from
September 2002 to August 2004 at the Department of Oncology,
University Hospital of Aarhus, Denmark (cohort A). Three patients
were excluded as the treatment represented re-induction with IL-2/
IFN after late progression of disease (N¼2) and because of lack of
confirmation of RCC at central review (N¼1), thus leaving 120
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spatients eligible for this study. Patients assigned for treatment had
histologically confirmed RCC, progressive metastatic disease,
ECOG performance status p2, age 18–70 years, adequate organ
function, and no brain metastases. Objective response was assessed
according to RECIST (Therasse et al, 2000). Stable disease was
defined as no progression at 6 months after initiation of treatment.
Overall survival time was defined as time from initiation of
treatment to time of death or last follow-up. Survival status was
updated on 24 August 2008. Clinical baseline data were retro-
spectively obtained through chart review. The presence of
comorbidity was retrospectively registered for all patients.
Concomitant medication was inadequately registered in the patient
records and was therefore not scored. No patients were lost to
follow-up. The local ethical committee approved the study.
For the assessment of histology subtype, tumour samples were
collected from the routine pathologic evaluation obtained at
primary diagnosis or at verification of recurrence and reviewed
centrally by a single senior pathologist (NM) according to UICC
(Storkel et al, 1997). Three patients could not be classified because
of insufficient tumour material and insufficient initial pathology
report, and were thus categorised as unclassified.
A second, independent cohort was used for validation of the
results. The validation-cohort consisted of 120 patients with mRCC
from the same institution (cohort B). These patients were treated
in different phase II trials with low or intermediate dose
subcutaneous IL-2 with or without IFN-a and histamine dihy-
drochloride from February 1999 to August 2002. Response rates
were defined according to WHO (Miller et al, 1981). Survival status
was updated on 30 November 2008. Data were prospectively
collected. The histological subtype in this cohort was also centrally
reviewed (NM). Clinical results of this patient group have been
published earlier (Donskov and von der Maase, 2006).
Treatment
Patients in cohort A were treated in an outpatient setting,
consisting of one priming-week of daily IFN-a followed by up to
six treatment cycles of 4 weeks with IFNa-2b (Introna, Schering-
Plough, Denmark, 3 MIU as a fixed dose s.c. once daily 5 days per
week throughout the treatment) and IL-2 (Aldesleukin, rIL-2,
Proleukin, Chiron, The Netherlands, 2.4MIUm
–2, s.c. two times
daily 5 days per week, weeks 1 and 2 every cycle). Assessment for
objective response was carried out every three cycles. Treatment
was discontinued in case of progressive disease or unacceptable
toxicity.
In all, 40 patients had second-line treatment after progression
with IL-2 and 15 had more than one treatment. Four patients were
re-induced with IL-2, 22 were included in a randomised phase III
trial with lapatinib vs. medroxyprogesteron, 12 were included in a
phase I/II study with dendritic cell vaccination and 2 patients were
included in a study with IL-21. Additional 14 patients were treated
with sorafenib and 5 patients with sunitinib.
Analysis of serum sodium
Serum sodium was performed as a part of the routine laboratory
assessment before treatment. Serum sodium was analysed using a
certified procedure ‘Cobas Integra 700’ until June 2004 and ‘Cobas
Integra 800’ from July 2004 (Palmer et al, 1995; Redondo et al,
2003).
Statistical methods
Uni- and multivariate survival analyses were based on Cox
proportional hazards regressions model. The univariate para-
meters with Po0.05 were used in the multivariate analyses using
backwards selection. The variables were tested for interaction
and the assumption for proportional hazards was verified. All
calculations were performed according to intention to treat. All
tests were two-sided, and Po0.05 was considered statistically
significant.
For the survival analysis, the variables were dichotomised.
Clinical factors: median age, 458 years vs p58 years; ECOG
performance status, X2 vs 0.1; weight loss, 410 vs p10%,
metastases-free interval, o1 vs X1 year; number of disease sites,
X3 vs 1.2, and sites of metastases (lung, bone, liver, primary
tumour in situ, adrenal gland, and lymph nodes) Biochemical
factors: serum sodium, below normal vs normal; haemoglobin,
below normal vs normal; leukocytes, above normal vs normal;
neutrophils, above normal vs normal; platelets, above normal vs
normal, plasma albumin, below normal vs normal; plasma calcium
at pH¼7.4, above normal vs normal; alkaline phosphatase, above
normal vs normal; lactate dehydrogenase, X1.5 upper normal limit
(UNL) vs o1.5 UNL; bilirubin, above normal vs normal; alanine
aminotransferase (ALAT), above normal vs normal.
Primary tumour in situ was not included in the multivariate
analysis because of close interaction with metastasis-free interval.
The dichotomised value of serum sodium was correlated with the
clinical and biochemical variables using Fisher’s exact test.
Statistical analyses were performed using Stata version 9.1 (Stata
Corp., 2003, College Station, TX, USA)
RESULTS
Clinical results
Baseline characteristics for cohort A are shown in Table 1. The
median age was 58.3 years and 68% were men. The median
survival time was 15.1 month (range: 0.3–71.0þ), and 103
patients had died by the end of follow-up. The estimated 5-year
survival rate was 15%, (Figure 1A). Of the 120 patients, 111 had
clear cell carcinoma, 4 papillary, 2 chromofobe, and 3 had
unclassified tumours.
On the basis of intention to treat, the overall response rate was
14%, including 3 patients with a complete response (3%) and 14
patients with a partial response (12%). Thirty-six patients (30%)
had stable disease for a minimum of 6 months and 47 (39%) had
progressive disease. Twenty patients (17%) were not evaluable for
response because of early treatment termination due to toxicity.
Fourteen patients (12%) had curative intended surgery of residual
disease after completed immunotherapy. A total of seven patients
(6%) had no evidence of disease at 49.1–71þ months after
treatment.
Serum sodium
In cohort A, serum sodium values ranged between 126 and 144mM
(mmoll
–1, median 138mM). Twenty-four patients (20%) had
sodium below the normal range (o136mM). Hyponatremia was
significantly associated with the following variables: performance
status (2þ), number of sites (3þ), primary tumour in situ, weight
loss 410%, and MSKCC poor risk group. Hyponatremia was also
significantly associated with the following biochemical variables:
leukocytes above normal, albumin below normal, alkaline
phosphatase above normal, and low haemoglobin (Table 2a).
Assessing patients with clear cell histology only (N¼111), similar
associations were observed, however, primary tumour in situ was
only marginally significant (P¼0.06).
Twenty patients (83%) with hyponatremia received three or less
series of IL-2. Nine of these discontinued early because of toxicity
and were as such not evaluable for response, whereas 11 had
progressive disease at first evaluation (after three treatment
cycles). In contrast, 51 (53%) patients with normal sodium levels
received more than three series of IL-2, because of response to
treatment or stable disease allowing for continuation of treatment
beyond the first evaluation (Table 2b).
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sIn general, comorbidity was infrequent and mild. Among the 24
patients with hyponatremia, 5 (21%) had hypertension, 1 (4%) had
sequelae from a cerebral insult, and 4 (17%) had diabetes mellitus.
For the 96 patients with normal level of natrium, 20 (21%) had
hypertension, 2 (2%) had previously had a cerebral insult, 3 (3%)
had previously had a myocardial infarction, 5 (5%) had diabetes
mellitus, and 4 (4%) had asthma or COPD.
Univariate survival analyses
Clinical factors significantly associated with short survival in
cohort A were: performance status (2þ), metastasis-free interval
(o1 year), number of metastatic sites (3þ), presence of bone-
metastases, primary tumour in situ, low serum sodium, blood
neutrophiles (4normal), serum albumin (onormal), and lactate
dehydrogenase (41.5UNL) (Table 3).
Patients with hyponatremia before treatment (N¼24) had a
median overall survival of only 5.5 months (range 0.3–64.1
months), whereas patients with normal sodium values at baseline
(N¼96) had a median survival of 18.6 months (range 0.7–71.0
months) (Po0.001) (Figure 1A). Two patients with low serum
sodium had a survival above 40 months. Both these patients had a
baseline serum sodium level of 134mM, just below normal value.
When analysing clear cell tumours only (N¼111), the identical
nine parameters were significantly associated with poor overall
survival.
Multivariate survival analysis
For cohort A, significant baseline parameters from the univariate
analyses were included in the multivariate analysis. Significant
independent risk factors for short survival were low serum sodium
(HR 1.90, CI 1.1–3.2, P¼0.014), neutrophils above normal (HR
1.75, CI 1.1–2.8, P¼0.018), lactate dehydrogenase 41.5ULN (HR
2.09, CI 1.3–3.3, P¼0.002), and number of metastatic sites (þ3)
(HR 1.92; CI 1.3–2.9, P¼0.003) (Table 4a). When analysing
patients with clear cell carcinomas only (N¼111), independent
factors for poor survival were performance status (2þ), metas-
tasis-free interval (o1 year), serum albumin (onormal), and
lactate dehydrogenase (41.5ULN).
Validation of baseline serum sodium as a prognostic factor
In the independent cohort (cohort B; N¼120), the range of serum
sodium was 128–148mM with a median value of 140mM. Patients
with baseline hyponatremia (N¼17) had a median overall survival
of only 4.8 months (range 0.5–24.2 months), whereas patients with
normal sodium values at baseline (N¼102) had a median survival
of 16.9 months (range 0.5–115.8 months) (Po0.001) (Figure 1B).
All long-term survivors had normal serum sodium level. In this
cohort B, low serum sodium was validated as an independent
prognostic factor for survival in the multivariate analysis (HR 2.98,
CI 1.54–5.77, P¼0.001) (Table 4b). Assessing clear cell carcino-
mas only in this cohort, serum sodium was also an independent
prognostic factor for survival in the multivariate analysis (HR 3.52,
CI 1.85–6.69, P¼0.000).
Sodium as a predictive factor
In both cohort A and B, hyponatremia was associated with lack of
response. In cohort A, 15 responders (88%), including all with a
Table 1 Baseline characteristics (N¼120), cohort A
N (%)













4 or more 33 (28)
Most common sites of disease
Lymph node 80 (67)
Lung/pleura 74 (62)
Primary kidney tumor 61 (51)
Liver 36 (30)
Bone 30 (25)
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Figure 1 (A) Survival and baseline serum sodium level, cohort A
(N¼120). (B) Survival and baseline serum sodium level, cohort B (N¼119).
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scomplete response, had normal baseline serum sodium levels.
In cohort B, 13 responders (87%) had normal serum sodium.
A significant association between lack of response and low serum
sodium was observed in both cohorts (P¼0.003 and P¼0.02,
respectively).
DISCUSSION
This study is to our knowledge the first to show and validate low
baseline serum sodium as a prognostic factor for short survival
and a predictive factor for lack of response in patients with mRCC
receiving IL-2-based therapy. Serum sodium is a readily available,
easily obtained and routinely measured plasma electrolyte. Thus,
hyponatremia may have the potential to be easily incorporated
into prognostic models optimising outcome prediction. Moreover,
patients with hyponatremia should have more intensive cancer
care as this patient group represents a subgroup with a dismal
prognosis with a median survival of only approximately 5 months.
Serum sodium has remained neglected as a significant clinical
feature despite being one of the most frequently obtained blood
tests in daily clinical practise. Most often, hyponatremia has been
underdiagnosed and untreated by medical staff. This is despite
hyponatremia is the most common electrolyte disorder in
hospitalised patients (Asadollahi et al, 2007; Patel and Balk,
2007). However, within the last few years, a large body of evidence
has emerged rendering hyponatremia as a strong general danger
signal in many disorders as liver cirrhosis (Luca et al, 2007; Kim
et al, 2008), congestive heart failure (Gheorghiade et al, 2007; Rossi
et al, 2007; Ghali, 2008; Gotsman et al, 2008; Rusinaru et al, 2009),
infections (Nair et al, 2007; Yaghoubian et al, 2007; Chao et al,
2008), and several cancers (Gandhi and Johnson, 2006; Kim et al,
2007; Huo et al, 2008; Kacprowicz and Lloyd, 2009). Thus,
hyponatremia may in fact be an important universal danger signal
and an indicator of poor prognosis. Therefore, the association in
localised RCC between hyponatremia and short disease free and
overall survival after nephrectomy (Vasudev et al, 2008) is in line
with these observations. Similarly, our findings in this study of
hyponatremia as an independent, validated predictive and
prognostic factor in mRCC just further emphasises and extends
the importance of hyponatremia as a significant risk feature.
The reason for hyponatremia in mRCC is largely unknown. In
both our cohorts presented in this study, the serum sodium below
normal range was only present in a minority of the patients (20%
and 14%, respectively). Strikingly, low values of serum sodium
were significantly associated with several clinical and biochemical
factors known to be associated with poor outcome, among others
Table 3 Overall survival, cohort A, univariate analyses (N¼120)
Risk factors Categories Median survival (months) Hazard ratio 95 % CI P
Performance status 2+/0.1 7.2/18.3 1.95 1.25–3.04 0.003
Metastasis-free interval o1/41 year 12.5/24.4 1.75 1.11–2.77 0.016
Number of sites 3+/1.2 11.4/23.3 1.71 1.15–2.54 0.008
Primary tumor +/  12.7/18.2 1.52 1.03–2.25 0.034
Bone metastases +/  10.2/18.2 1.96 1.27–3.02 0.002
Serum sodium Low/normal 5.5/18.6 2.43 1.51–3.92 0.000
Neutrophils 47/o7 9.4/20.2 1.66 1.05–2.61 0.030
Albumin Low/normal 8.9/21.8 1.88 1.27–2.78 0.002
LDH 41.5/o1.5ULN 10.0/20.2 1.77 1.12–2.80 0.014
Table 2a Correlation between baseline factors and serum sodium,
cohort A
Serum sodium
Low (N¼24) Normal (N¼96) P
MSKCC (N¼115) N (%) N (%) 0.001
Favourable (N¼15) 0 (0) 15 (16)
Intermediate (N¼65) 8 (36) 57 (61)
Poor (N¼35) 14 (64) 21 (23)
Weight loss (N¼119) 0.001
p10% (N¼95) 13 (54) 82 (86)
410% (N¼24) 11 (46) 13 (14)
Performance status (N¼120) 0.000
0.1 (N¼91) 8 (33) 83 (86)
2+ (N¼29) 16 (67) 13 (14)
Number of sites (N¼120) 0.020
1.2 (N¼52) 5 (21) 47 (49)
3+ (N¼68) 19 (79) 49 (51)
Primary tumor in place (N¼120) 0.039
No (N¼59) 7 (29) 52 (54)
Yes (N¼61) 17 (71) 44 (46)
Leukocytes (N¼120) 0.029
Normal (N¼92) 14 (58) 78 (81)
High (N¼28) 10 (42) 18 (19)
Albumin (N¼119) 0.000
Normal (N¼68) 2 (8) 66 (69)
Low (N¼51) 22 (92) 29 (31)
Alkalic phosphatase (N¼118) 0.004
Normal (N¼71) 7 (29) 64 (67)
High (N¼47) 15 (63) 32 (33)
Haemoglobin (N¼120) 0.000
Normal (N¼56) 2 (8) 54 (56)
Low (N¼64) 22 (92) 42 (44)
Table 2b Correlation between treatment factors and serum sodium,
cohort A
Serum sodium
Low (N¼24) Normal (N¼96) P
Response (N¼120) N (%) N (%) 0.003
CR + PR (N¼17) 2 (8) 15 (16)
SD (N¼36) 2 (8) 34 (35)
PD (N¼47) 11 (46) 36 (38)
NE (N¼20) 9 (38) 11 (11)
Duration of IL-2 (N¼120) 0.001
p3 months (N¼65) 20 (83) 45 (47)
43 months (N¼55) 4 (17) 51 (53)
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spoor performance status, weight loss, low haemoglobin, and
MSKCC poor risk grouping. Importantly, patients with hyponatre-
mia did not have a higher frequency of comorbidity than patients
with normal natrium. Comorbidity is therefore an unlikely
explanation for the dismal prognosis for patients with hyponatremia.
Cancer may be accompanied by paraneoplastic phenomenons
causing hyponatremia and hypercalcaemia, among others
(Kacprowicz and Lloyd, 2009). In small cell lung cancer, the syn-
drome of inappropriate anti-diuretic hormone secretion (SIADH
or Schwartz Batter syndrome) is well described and has been
associated with a reduced survival (Gandhi and Johnson, 2006).
The SIADH is a likely explanation, however, no reports on
SIADH-disturbances exist in RCC. In this study, we were not able
to assess whether hyponatremia was associated with SIADH, but
the potential association should be examined in future pros-
pective studies.
Other explanations for low sodium may be poor function of the
adrenal glands (Yokoyama and Tanaka, 2005; Bahrami et al, 2009).
However, in our material, there was no statistical correlation
between low serum sodium and neprectomy, adrenalectomy, or
adrenal metastasis. Another reason may be a renal dysfunction in
the exchange mechanism of sodium in the tubules. Taken together,
these potential mechanisms remain speculative and further studies
are needed to rule out the mechanisms behind low serum sodium.
The serum sodium value used for prognostication was based on
a single laboratory value measured before initiation of treatment in
all patients. For the electronic devise measuring the level of serum
sodium, a high specificity and sensitivity has been shown (Palmer
et al, 1995; Redondo et al, 2003). Moreover, the assessment is easy,
cheap, reliable, and reproducible.
Limitations of this study are the relative low sample size in both
cohorts and the retrospective evaluation of cohort A. We did not
analyse the day-to-day variation in serum sodium. No complete
data on concomitant medication were available and therefore, we
have been unable to correct for use of diuretics.
In conclusion, hyponatremia is a new independent prognostic
and predictive factor in patients with mRCC. Further investiga-
tions are needed to examine the mechanisms behind hyponatremia
and the association with cancer.
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